Lenvatinib (Lenvima®)
Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
Rapid Review
| Commenced | Completed | Outcome |
| 05/05/2015 | 09/07/2015 | Full pharmacoeconomic evaluation recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations. January 2016.